UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

The American journal of psychiatry, 2008-08, Vol.165 (8), p.1033-1039

2008

Volltextzugriff (PDF)

Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection

Pharmacological reviews, 2008-09, Vol.60 (3), p.358-403

2008

Volltextzugriff (PDF)

Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: Implications for treatment of attention-deficit hyperactivity disorder

Synapse (New York, N.Y.), 2012-06, Vol.66 (6), p.522-532

2012

Volltextzugriff (PDF)

A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder

Psychopharmacology, 2013-03, Vol.226 (2), p.189-200

2013

Volltextzugriff (PDF)

A Novel Augmentation Strategy for Treating Resistant Major Depression

The American journal of psychiatry, 2001-01, Vol.158 (1), p.131-134

2001

Volltextzugriff (PDF)

Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System

Journal of medicinal chemistry, 2000-11, Vol.43 (23), p.4333-4353

2000

Volltextzugriff (PDF)

Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

Neuropsychopharmacology (New York, N.Y.), 1996-02, Vol.14 (2), p.87-96

1996

Volltextzugriff (PDF)

Muscarinic mechanisms in psychotic disorders

Handbook of experimental pharmacology, 2012 (213), p.233

2012

Volltextzugriff (PDF)

Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder

Neuropsychopharmacology (New York, N.Y.), 2002-11, Vol.27 (5), p.699-711

2002

Volltextzugriff (PDF)

Case history: the discovery of fluoxetine hydrochloride (Prozac)

Nature reviews. Drug discovery, 2005-09, Vol.4 (9), p.764-774

2005

Volltextzugriff (PDF)

Duloxetine Increases Serotonin and Norepinephrine Availability in Healthy Subjects: A Double-Blind, Controlled Study

Neuropsychopharmacology, 2003-09, Vol.28 (9), p.1685-1693

2003

Volltextzugriff (PDF)

Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors

Neuropsychopharmacology (New York, N.Y.), 2001-12, Vol.25 (6), p.871-880

2001

Volltextzugriff (PDF)

Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the MPTP Model of Parkinson's Disease

Proceedings of the National Academy of Sciences - PNAS, 2001-12, Vol.98 (25), p.14669-14674

2001

Volltextzugriff (PDF)

The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression

Current pharmaceutical design, 2005-05, Vol.11 (12), p.1475-1493

2005

Volltextzugriff (PDF)

Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium

European journal of pharmacology, 2000-03, Vol.390 (3), p.245-248

2000

Volltextzugriff (PDF)

R-fluoxetine Increases Extracellular DA, NE, As Well As 5-HT in Rat Prefrontal Cortex and Hypothalamus: An in vivo Microdialysis and Receptor Binding Study

Neuropsychopharmacology (New York, N.Y.), 2002-12, Vol.27 (6), p.949-959

2002

Volltextzugriff (PDF)

Muscarinic mechanisms of antipsychotic atypicality

Progress in neuro-psychopharmacology & biological psychiatry, 2003-10, Vol.27 (7), p.1125-1143

2003

Volltextzugriff (PDF)

Dual monoamine modulation for improved treatment of major depressive disorder

Journal of clinical psychopharmacology, 2003-02, Vol.23 (1), p.78-86

2003

Volltextzugriff (PDF)

Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles

Circulation (New York, N.Y.), 2004-06, Vol.109 (25), p.3202-3207

2004

Volltextzugriff (PDF)

Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication

Life Sciences, 1995, Vol.57 (5), p.411-441

1995

Volltextzugriff (PDF)

Muscarinic receptors as a target for drugs treating schizophrenia

Current drug targets. CNS & neurological disorders, 2002-04, Vol.1 (2), p.163-181

2002

Volltextzugriff (PDF)

A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data

International journal of geriatric psychiatry, 2001-12, Vol.16 (S1), p.S33-S61

2001

Volltextzugriff (PDF)

Current perspectives on the development of non-biogenic amine-based antidepressants

Pharmacological research, 2001-05, Vol.43 (5), p.411-422

2001

Volltextzugriff (PDF)

Amantadine for weight gain associated with olanzapine treatment

European neuropsychopharmacology, 2005, Vol.15 (1), p.13-21

2005

Volltextzugriff (PDF)

Elucidating the role of muscarinic receptors in psychosis

Life sciences (1973), 2001-04, Vol.68 (22), p.2605-2613

2001

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(44)

Sprache

Englisch
(44)
Japanisch
(22)

Erscheinungsjahr

n.n

Thema

Animals
(34)
Science & Technology
(32)
Life Sciences & Biomedicine
(30)
Pharmacology & Pharmacy
(21)
Biological And Medical Sciences
(19)
Medical Sciences
(19)
Male
(18)
Pharmacology. Drug Treatments
(17)
Neuropharmacology
(16)
Psychiatry
(14)
Neurosciences & Neurology
(13)
Psychopharmacology
(13)
Psychology. Psychoanalysis. Psychiatry
(12)
Rats
(12)
Muscarinic Agonists - Pharmacology
(11)
Neurosciences
(11)
Cricetinae
(9)
Dose-Response Relationship, Drug
(9)
Receptors, Muscarinic - Metabolism
(9)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection

Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: Implications for treatment of attention-deficit hyperactivity disorder

A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder

A Novel Augmentation Strategy for Treating Resistant Major Depression

Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System

Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

Muscarinic mechanisms in psychotic disorders

Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder

Case history: the discovery of fluoxetine hydrochloride (Prozac)

Duloxetine Increases Serotonin and Norepinephrine Availability in Healthy Subjects: A Double-Blind, Controlled Study

Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors

Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the MPTP Model of Parkinson's Disease

The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression

Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium

R-fluoxetine Increases Extracellular DA, NE, As Well As 5-HT in Rat Prefrontal Cortex and Hypothalamus: An in vivo Microdialysis and Receptor Binding Study

Muscarinic mechanisms of antipsychotic atypicality

Dual monoamine modulation for improved treatment of major depressive disorder

Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles

Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication

Muscarinic receptors as a target for drugs treating schizophrenia

A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data

Current perspectives on the development of non-biogenic amine-based antidepressants

Amantadine for weight gain associated with olanzapine treatment

Elucidating the role of muscarinic receptors in psychosis

Aktive Filter

Suchergebnisse filtern